Vaxart, Inc. (NASDAQ:VXRT) was the target of unusually large options trading on Wednesday. Traders purchased 47,388 put options on the company. This represents an increase of 1,061% compared to the average daily volume of 4,080 put options.
A number of research analysts recently issued reports on the company. Zacks Investment Research downgraded Vaxart from a “hold” rating to a “sell” rating in a report on Saturday, November 14th. B. Riley reiterated a “buy” rating and set a $22.00 price objective on shares of Vaxart in a report on Thursday, December 3rd.
In related news, Director Wouter Latour sold 333,334 shares of the stock in a transaction dated Monday, November 23rd. The stock was sold at an average price of $6.32, for a total transaction of $2,106,670.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.30% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of VXRT. Point72 Hong Kong Ltd acquired a new position in Vaxart during the third quarter valued at approximately $34,000. Heritage Wealth Advisors lifted its position in shares of Vaxart by 268.5% in the fourth quarter. Heritage Wealth Advisors now owns 9,950 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 7,250 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Vaxart in the fourth quarter valued at approximately $59,000. Townsquare Capital LLC acquired a new stake in shares of Vaxart in the third quarter valued at approximately $68,000. Finally, Raymond James & Associates acquired a new stake in shares of Vaxart in the third quarter valued at approximately $70,000. 17.90% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ VXRT opened at $9.85 on Thursday. The stock has a 50 day moving average price of $7.79 and a 200 day moving average price of $7.45. Vaxart has a 52 week low of $0.97 and a 52 week high of $24.90. The stock has a market capitalization of $1.08 billion, a PE ratio of -16.69 and a beta of -0.11.
Vaxart (NASDAQ:VXRT) last issued its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. Vaxart had a negative return on equity of 84.90% and a negative net margin of 281.50%. The firm had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $1.60 million. As a group, sell-side analysts forecast that Vaxart will post -0.35 earnings per share for the current fiscal year.
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine.
Further Reading: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Vaxart Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vaxart and related companies with MarketBeat.com’s FREE daily email newsletter.